Eli Lilly's (LLY) tirzepatide Has Multi-Billion Opportunities Outside of Diabetes, Currently Undervalued - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY) in light ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
